CA2138643A1 - Use of rifamycin derivatives for the manufacture of a medicament for the treatment of toxoplasmosis - Google Patents

Use of rifamycin derivatives for the manufacture of a medicament for the treatment of toxoplasmosis

Info

Publication number
CA2138643A1
CA2138643A1 CA002138643A CA2138643A CA2138643A1 CA 2138643 A1 CA2138643 A1 CA 2138643A1 CA 002138643 A CA002138643 A CA 002138643A CA 2138643 A CA2138643 A CA 2138643A CA 2138643 A1 CA2138643 A1 CA 2138643A1
Authority
CA
Canada
Prior art keywords
infection
spiropiperidyl
ring
combination
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002138643A
Other languages
English (en)
French (fr)
Inventor
Jack S. Remington
Fausto G. Araujo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Palo Alto Medical Research Foundation
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/203,539 external-priority patent/US5529994A/en
Application filed by Individual filed Critical Individual
Publication of CA2138643A1 publication Critical patent/CA2138643A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
CA002138643A 1993-05-05 1994-04-29 Use of rifamycin derivatives for the manufacture of a medicament for the treatment of toxoplasmosis Abandoned CA2138643A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5728893A 1993-05-05 1993-05-05
US08/057,288 1993-05-05
US08/203,539 1994-02-28
US08/203,539 US5529994A (en) 1993-05-05 1994-02-28 Treatment for toxoplasmosis

Publications (1)

Publication Number Publication Date
CA2138643A1 true CA2138643A1 (en) 1994-11-10

Family

ID=26736295

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002138643A Abandoned CA2138643A1 (en) 1993-05-05 1994-04-29 Use of rifamycin derivatives for the manufacture of a medicament for the treatment of toxoplasmosis

Country Status (14)

Country Link
US (5) US5665707A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0648121B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPH07509003A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE143601T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU669300B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2138643A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69400631T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0648121T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2095772T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3021828T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL109543A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO950030L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2121838C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1994025038A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9224739D0 (en) * 1992-11-26 1993-01-13 Wellcome Found Medicaments
GB9424013D0 (en) * 1994-11-29 1995-01-18 Wellcome Found Medicaments
US6710033B1 (en) 1996-08-14 2004-03-23 Vanderbilt University Methods and treatment of multiple sclerosis
US6258532B1 (en) 1997-08-14 2001-07-10 Vanderbilt University Methods for in vitro susceptibility testing of chlamydia
US6579854B1 (en) 1996-08-14 2003-06-17 Vanderbilt University Diagnosis and management of infection caused by chlamydia
US6890526B2 (en) 1997-05-06 2005-05-10 Vanderbilt University Methods and reagents for the treatment of multiple sclerosis
AU3760400A (en) * 1999-03-19 2000-10-09 Vanderbilt University Methods and reagents for the diagnosis and treatment of multiple sclerosis
US6429231B1 (en) * 2001-09-24 2002-08-06 Bradley Pharmaceuticals, Inc. Compositions containing antimicrobials and urea for the treatment of dermatological disorders and methods for their use
US7074832B2 (en) 2001-09-24 2006-07-11 Bradley Pharmaceuticals, Inc. Compositions containing antimicrobials and urea for the treatment of dermatological disorders and methods for their use
JP2003327536A (ja) * 2002-03-07 2003-11-19 Kitasato Inst:The ヒト免疫不全症候群ウイルスの感染、増殖抑制剤
US6858083B2 (en) * 2002-06-05 2005-02-22 Scimed Lifesystems, Inc. Apparatus and method for closed-loop control of RF generator for welding polymeric catheter components
US20030017985A1 (en) * 2002-07-02 2003-01-23 Taylor Gregory Alan Molecules that influence pathogen resistance
RU2255730C1 (ru) * 2003-10-14 2005-07-10 Федеральное государственное унитарное предприятие "Всероссийкий научный центр по безопасности биологически активных веществ" (ФГУП "ВНЦ БАВ") Стабильная фармацевтическая суспензия азитромицина и способ ее получения
DE102004055316A1 (de) * 2004-11-16 2006-05-18 Bayer Healthcare Ag Verhinderung vertikaler Endoparasiten-Infektionen
TWI368509B (en) 2005-10-05 2012-07-21 Otsuka Pharma Co Ltd Antituberculous therapeutic drugs and kit containing the same
US7799885B2 (en) 2005-11-30 2010-09-21 Corning Incorporated Photo or electron beam curable compositions
US20090054380A1 (en) * 2005-12-20 2009-02-26 Greenstein Robert J Methods for diagnosing and treating a mycobacterium avium subspecies paratuberculosis infection
SG10201405158QA (en) * 2006-02-24 2014-10-30 Callida Genomics Inc High throughput genome sequencing on dna arrays
RU2320337C1 (ru) * 2006-06-09 2008-03-27 Федеральное государственное унитарное предприятие "Государственный научный центр по антибиотикам" Способ получения антимикробной композиции с рифабутином
FR2944014A1 (fr) 2009-04-06 2010-10-08 Univ Grenoble 1 Peptides cycliques a activite antiparasitaire
CN114601840A (zh) * 2020-12-08 2022-06-10 复旦大学附属中山医院 一种联合用药,用于治疗卡氏肺孢子虫肺炎
CN113230248A (zh) * 2021-06-18 2021-08-10 宁波大学 利卡灵-b及其组合物在制备治疗或预防弓形虫病药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3644616A (en) * 1969-03-24 1972-02-22 Ciba Geigy Corp Synergistic composition of rifampicin and streptomycin
US4054663A (en) * 1974-12-23 1977-10-18 Sankyo Company Limited Pyridine derivatives and their use as anticoccidial agents
US4094982A (en) * 1975-05-15 1978-06-13 Sankyo Company Limited Pyridine sulfonamides and their use as anticoccidial agents
IT1056272B (it) * 1975-06-13 1982-01-30 Archifar Ind Chim Trentino Prodotti derivati dalle amine aromatiche
IT1135270B (it) * 1980-04-12 1986-08-20 Erba Farmitalia 3-amidino-ansamicine
US5053432A (en) * 1983-04-14 1991-10-01 Burroughs Wellcome Co. Naphthoquinone derivatives
US5175319A (en) * 1983-04-14 1992-12-29 Burroughs Wellcome Co. Naphthoquinone derivatives
DE3512194A1 (de) * 1985-04-03 1986-10-09 Hoechst Ag, 6230 Frankfurt Ein neues ansamycin-antibiotikum, ein mikrobielles verfahren zu seiner herstellung und seine verwendung als arzneimittel
WO1989002271A1 (en) * 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents
GB9000241D0 (en) * 1990-01-05 1990-03-07 Coopers Animal Health Pharmaceutical use
US5529994A (en) * 1993-05-05 1996-06-25 Palo Alto Medical Foundation Treatment for toxoplasmosis

Also Published As

Publication number Publication date
DE69400631T2 (de) 1997-02-27
NO950030D0 (no) 1995-01-04
AU6905094A (en) 1994-11-21
ES2095772T3 (es) 1997-02-16
DE69400631D1 (de) 1996-11-07
NO950030L (no) 1995-01-04
US5670496A (en) 1997-09-23
US5650405A (en) 1997-07-22
US5641769A (en) 1997-06-24
GR3021828T3 (en) 1997-02-28
EP0648121B1 (en) 1996-10-02
WO1994025038A1 (en) 1994-11-10
EP0648121A1 (en) 1995-04-19
IL109543A0 (en) 1994-08-26
ATE143601T1 (de) 1996-10-15
RU95105973A (ru) 1997-01-20
JPH07509003A (ja) 1995-10-05
IL109543A (en) 1998-06-15
RU2121838C1 (ru) 1998-11-20
US5648345A (en) 1997-07-15
AU669300B2 (en) 1996-05-30
DK0648121T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1997-02-24
US5665707A (en) 1997-09-09

Similar Documents

Publication Publication Date Title
CA2138643A1 (en) Use of rifamycin derivatives for the manufacture of a medicament for the treatment of toxoplasmosis
ES2349458T3 (es) Derivados o-metilados de rapamicina para aliviar e inhibir trastornos.
ES2608285T3 (es) Procedimientos para el tratamiento de paludismo, tuberculosis y enfermedades por MAC
Thompson et al. Animal models for studying the action of topoisomerase I targeted drugs
US8435992B2 (en) Multiple myeloma treatments
US20120053559A1 (en) Treatment of Proliferative Diseases with Epothilone Derivatives and Radiation
EP1463504B1 (en) Compositions comprising epothilones and their use for the treatment of the carcinoid syndrome
US5529994A (en) Treatment for toxoplasmosis
AU2009227092B2 (en) Combination of a bis-thiazolium salt or a precursor thereof and artemisinin or a derivative thereof for treating acute malaria
ES2994600T3 (en) Combination of quinoline-4-carboxamides and benzonaphthyridine derivatives as antimalarial drug combination
US20210161892A1 (en) Composition including rilpivirine and method for treating tumors or cancer
Chang et al. Activity of epiroprim (Ro 11-8958), a dihydrofolate reductase inhibitor, alone and in combination with dapsone against Toxoplasma gondii
KR20250099049A (ko) 투명세포 신세포 암종의 치료
Hawryluk et al. Onchocerciasis drug discovery
Pedersen The influence of calcium antagonists on plasma digoxin concentration
CA2167843A1 (en) Method of treating hiv with azaspiranes
AU7370994A (en) Method of inhibiting the replication of human immunodeficiency viruses with substituted azaspiranes
AU2002366531B2 (en) Compositions comprising epothilones and their use for the treatment of carcinoid syndrome
ZA200404013B (en) Compositions comprising epothilones and their use for the treatment of carcinoid syndrome.
HK1069983B (en) Compositions comprising epothilones and their use for the treatment of the carcinoid syndrome

Legal Events

Date Code Title Description
FZDE Discontinued